Navigation Links
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine

Vaxfectin(TM) may have potential applications as an adjuvant for other protein-based vaccines as well. The company holds patents in the United States covering Vaxfectin(TM) and its use with conventional vaccines against infectious diseases and cancer, and in both the United States and Europe covering the use of Vaxfectin(TM) with DNA vaccines.

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue evaluation of Vaxfectin(TM) as an adjuvant for conventional vaccines against seasonal or pandemic influenza; whether Vaxfectin(TM) will be used as a dose-sparing agent with conventional influenza vaccines against seasonal or pandemic influenza strains; whether Vical or others will continue development of the pandemic influenza DNA vaccine cand
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... VIEW, Calif., July 31, 2014 IRIDEX Corporation (Nasdaq: ... second quarter and six months ended June 28, 2014.  ... of 2014, up 15% from $9.2 million in the 2013 ... first quarter of 2014. Revenues for the first six months ... in the first six months of last year. , ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5
... Medical Marijuana Inc. (OTC: MJNA) is proud to ... of PharmaSphere, LLC. PharmaSphere, a cutting edge biotechnology company ... value bio-compounds sourced from plants that can be used ... (genetically engineered plants) for the biotechnology revolution is the ...
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
Cached Medicine Technology:Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics 2Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics 3Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics 4FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:7/31/2014)... July 31, 2014 (HealthDay News) -- Transplant surgeons ... red flags for burnout, a new study suggests. ... the study reported having a low sense of ... to feeling emotionally exhausted, researchers found. "Burnout ... like transplantation," study co-author Dr. Marwan Abouljoud, director ...
(Date:7/31/2014)... Scientists have learned that recent fears of invasive lionfish ... efforts to control lionfish by fishing derbies and targeted ... invasion. And there,s a simple way to know for ... after it,s been cooked. , Pacific lionfish were first ... and have been gaining swiftly in number ever since. ...
(Date:7/31/2014)... July 31, 2014 Millions of people ... have had traumatic experiences as a child and some ... work. As a highly experienced NJ cosmetic dentist, ... anxiety during their dental procedure. To help these ... team at Champagne Smiles offer several sedation dentistry techniques. ...
(Date:7/31/2014)... Scotch Plains, New Jersey (PRWEB) July 31, 2014 ... certified dermatologist by the American Board of Dermatology, fellowship ... approved again by NJ Top Docs. , After extensive ... the National Institutes of Health, Dr. Li completed his ... dermatology training at the University of Pennsylvania in Philadelphia. ...
(Date:7/31/2014)... York (PRWEB) July 31, 2014 ... as Bernstein Liebhard LLP notes that Johnson & ... plans to voluntarily remove its power morcellators ( ... report from Bloomberg.com, the company said it decided ... associated with the devices remain uncertain.* , “In ...
Breaking Medicine News(10 mins):Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... Goodwin HealthDay Reporter , THURSDAY, May 10 ... children have little or no label information about drug ... "We still have a long way to go," ... of the U.S. Food and Drug Administration,s Office of ...
... , THURSDAY, May 10 (HealthDay News) -- A ... U.S. Food and Drug Administration showed promising results in ... took Qnexa, a combination of the drugs phentermine and ... many weight-related health problems, the study found. The findings ...
... a low haemoglobin (Hb) level do not respond well to ... survival are compromised. Now researchers from The Netherlands have found ... can be overcome by the use of a treatment known ... carbogen (a mixture of carbon dioxide and oxygen) and the ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... 2012) A review of 30 years of life-threatening asthma ... annual ICU admissions for the condition have dropped 74 percent. ... cases at University Hospital between 1980 and 2010, also showed ... not result in longer hospital stays. UT Medicine is ...
... severe complications from systemic sclerosis, also known as scleroderma, ... Rheumatism , a journal of the American College of ... were more likely to have antibodies that increased frequency ... decreased survival. According to the ACR there ...
Cached Medicine News:Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 2Health News:Only Half of Meds Taken by Kids Have 'Adequate' Safety Info: Study 3Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 2Health News:Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels 3Health News:Economic theory actually works in health care 2Health News:ICU stays for worst asthma drop 74 percent, review finds 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: